Research programme: aziridine aldehyde-based macrocycle therapeutics - Encycle Therapeutics

Drug Profile

Research programme: aziridine aldehyde-based macrocycle therapeutics - Encycle Therapeutics

Alternative Names: Cyclic peptidomimetic - Encycle Therapeutics; Integrin α 4 beta 7 inhibitors- Encycle Therapeutics; Nacellins - Encycle Therapeutics; SMURF2 modulators - Encycle Therapeutics

Latest Information Update: 25 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Encycle Therapeutics
  • Developer Encycle Therapeutics; MaRS Innovation; University of Montreal
  • Class Macrocyclic compounds; Peptidomimetics
  • Mechanism of Action Alpha4-beta7 integrin antagonists; Ubiquitin protein ligase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Fibrosis; Inflammatory bowel diseases

Most Recent Events

  • 01 Nov 2017 Encycle Therapeutics and Pfizer enter into a research collaboration to optimise nacellins
  • 21 Nov 2016 Early research in Cancer in Canada (unspecified route)
  • 10 Nov 2014 Encycle Therapeutics, the University of Montreal and MaRS Innovation collaborates to develop nacellins in Canada for Inflammatory bowel disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top